leadf
logo-loader
viewCB Therapeutics

CB Therapeutics achieved the successful biosynthesis of psilocybin, psilocin

CB Therapeutics CEO Sher Butt joined Steve Darling with news the company has recently hit another milestone finding, in early testing, the analysis of raw analytical samples has shown the biosynthetic process of psilocybin, psilocin and related tryptamine-based compounds to be significantly more efficient, of higher purity and less expensive than existing chemical and biosynthetic techniques or other production methods. Butt talks about that and some of the next steps of the company as they prepare to start generating revenue.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

GlobeX Data close to finalizing a distribution deal in Canada for its...

GlobeX Data Ltd (CSE:SWIS) (OTCQB:SWISF) CEO Alain Ghiai caught up with Proactive to talk about how the group has reached the “final stages” of signing a distribution deal in Canada for its SekurSafe and Sekur solutions. Ghiai says the Toronto-based tech company's distribution deal is being...

13 hours, 50 minutes ago

2 min read